tremelimumab

Action and Spectrum

Drug Interaction

Adverse Reaction

Black Box Warning

Contraindication / Caution

Tremelimumab is contraindicated in patients hypersensitive to the formulation’s active ingredient and other excipients. 

Pregnancy / Lactation

Pregnancy consideration:  

No data is available regarding the usage during pregnancy. 

Breastfeeding warnings:  

Lactation is not advised until 3 months after the last dose. 

Pregnancy category: 

• Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.        
• Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women        
• Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.       
• Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.        
• Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.        
• Category N: There is no data available for the drug under this category

Pharmacology

Adminstartion

Patient Information Leaflet

Patient information leaflet 

Generic Name: tremelimumab 

Pronounced: treme-li-mum-ab 

Why do we use tremelimumab? 

Tremelimumab belongs to the category of antineoplastics. It helps to treat hepatocellular carcinoma and non-small lung cancer.